UT-SAVIA-HEALTH
12.12.2022 13:53:42 CET | Business Wire | Press release
SaVia Health, a clinician-led healthcare SaaS company that creates and embeds patient care processes alongside electronic medical records (EMR), announced it raised an $8.5 million Seed round. The round was led by Intel Capital with participation from Kickstart, Peterson Ventures, Tom Burton, the founder of Health Catalyst, and Dr. Brent James, a professor at Stanford and renowned luminary in the healthcare quality improvement field.
SaVia Health was founded by a clinician, Dr. Will Caldwell, and a group of veteran healthcare software engineers led by David Edwards based in Salt Lake City, UT, seeking to provide clinicians with the ability to self-author clinical care pathways and provide clinical advice at the point of care.
“When I first saw clinicians using the SaVia tools, I knew the platform was something special. Never in my 21 years of clinical practice have I seen a piece of technology so fiercely embraced by clinicians,” said Dr. Will Caldwell, co-founder and CEO of SaVia Health. “Clinicians can finally design, implement, and modify care processes in a way that mirrors the rapidly evolving clinical landscape.”
“SaVia is a game changer when it comes to process redesign that enables deep operational and clinical improvement,” said Tom Burton, co-founder and Strategic Advisor of Health Catalyst. “With SaVia, dynamic workflow data capture changes can be made in minutes rather than weeks or months accelerating the speed of process improvement.”
Today, SaVia Health provides clinicians and administrators with a versatile software tool that transforms paper-based care processes into digital workflows, embedding them directly into the EMR. As a result, clinicians have real-time clinical advice at their fingertips. By standardizing care along best practice guidelines, mistakes are avoided and patients achieve better outcomes.
“Intermountain [Healthcare] caregivers have been using SaVia’s technology for years to provide the best possible care to our patients. SaVia’s tools enable front-line caregivers to consistently deliver best practices as part of their clinical workflows,” said Raj Srivastava, Senior Medical Executive Director at Intermountain Healthcare Delivery Institute. “We are thrilled to continue partnering with SaVia as an independent company to continue improving patient outcomes.”
“Patient care faces several challenges, including smoothly integrating the latest technology into existing processes,” said Nick Washburn, Senior Managing Director at Intel Capital. “SaVia is seamlessly changing the game for clinicians by translating data into guidance on what steps to take and when to best serve each patient.”
With this funding round, the company will further develop the self-authoring platform, expand its existing library of off-the-shelf applications, and focus on rapidly driving sales.
About SaVia Health
SaVia Health is a healthcare technology company based in Salt Lake City, UT that provides SaaS based process improvement software targeted at health systems, self-insured corporations, and large physician groups both in the United States and abroad. To learn more, visit saviahealth.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221212005152/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom